Aurigene Pharmaceutical Services provides a flexible and wide range of services and capabilities at each phase of drug lifecycle.
- End-to-end services across the drug lifecycle.
- Integrated services and resources enabling seamless and accelerated development from discovery to commercialization.
- Capabilities to supply from gram scale to multi-ton scale of active ingredients and complex intermediates.
- Core areas of competence in specialized chemistry (peptides, carbohydrates, steroids, mPEGs).
- Standalone and integrated discovery services.
- World-class infrastructure: State-of-the-art R and D and manufacturing facilities audited by major international regulatory agencies.
- Biotherapeutic modalities including proteins, antibodies, ADCs, CAR Ts, mRNAs.
- Drug product capabilities from formulation development to commercial production in GMP facilities.
Hit Generation
Lead
IdentificationLead
Optimization
- Early stage drug discovery accelerating innovations for small and large molecules.
- FTE/FFS services in medicinal chemistry, computational chemistry, discovery biology. and large molecule modalities.
Development
Phase 1Development:
Phase 2Development:
Phase 3
- Helping our partners to bring their innovations to the market faster through phase appropriate development services.
- Process development and non-GMP supplies and technology transfer.
- GMP clinical supplies for API and drug product.
Commercial
Manufacturing
- Ensuring a sustainable supply of APIs and finished formulations.
- Continuous improvement and reliable commercial supplies from 8 US FDA inspected facilities.
Range of our services
Aurigene Pharmaceutical Services offers end-to-end capabilities across drug discovery, development and manufacturing of APIs and formulations. We have discovery, development and manufacturing operations in multiple technology platforms including carbohydrates, steroids, PEG derivatives, oligonucleotides, steroids, high-potent APIs and peptides. In addition, we run discovery scale and CDMO scale operations in biotherapeutics services such as ADCs, mAbs, mRNAs and CAR Ts.
Aurigene Pharmaceutical Services CRO/CDMO
Small
Molecules
Discovery
Discovery Chemistry
Library Synthesis, Peptide Synthesis, PROTAC Synthesis, Oligonucleotide synthesis
Discovery Biology
CADD and Informatics
Integrated
Drug
Discovery
Development Specialized Chemistry
Peptides High-potent, mPEGs, Carbohydrates, Steroids
Large Molecules
Biotherapeutics
Discovery Therapeutic Modalities
Monoclonal Antibody (mAb), Antibody Drug Conjugate (ADC), mRNA, Viral vectors, Cell Therapy
Development and Manufacturing
Monoclonal antibody
Protein therapeutics
Plasmid
Formulation
Services
Formulation Services
Eartly phase formulation development, Preformulation, Drug product characterization studies and testing, Pharmaceutical stability studies
Dosage Forms and Integrated DS-DP
Why Aurigene Pharmaceutical Services?
Our focus on scientific expertise and integrated services along with our strong fundamentals on quality infrastructure, sustainability operations, and information security makes us a preferred partner.
Truly integrated services
We offer one-stop solutions for
- Integrated Discovery chemistry and Biology services
- Small molecule and Large molecule services
- Services from early discovery to commercialization
- Global regulatory and quality expertise
- Pre-formulation and formulation service
- Analytical and purification expertise
Quality
- Our R and D site is US FDA inspected cGMP sites have multiple accreditations across globe, All our labs are GLP approved, animal facilities are AAALAC accredited
Science
- Strong technology platforms Niche/Sensitive/Complex chemistry expertise
Infrastructure
- 2 R and D centers, 8 US FDA inspected cGMP sites, AAALAC accredited vivarium
Information Security
- 360-degree information security coverage with adequate back-up plan, business continuity plan and information security interventions
Business Continuity
- Structured assurance and governance measures
People
- We strive to hire the best talent and train them,
700+ scientists, >95% of scientists are post-graduates or above
ESG
- Commitment to highest standards of Environment, Social and Governance; Dow Jones, CDP, PSCI, approved
Contact Us
Resources
MAY 19, 2023
“Bathtub Chemistry” - Necessity and Aspects of Process Research
Medicine is an essential part of our life. Since ancient time human civilization has been tirelessly engaged to understand the cause and effect of a disease. Sometimes they win and many times they loss. But the story of their curiosity and enthusiasm is a never damping process. On the contrary it increases day by day, year after year.  ...
Read More
Building successful long-term partnerships with CDMOs from early drug discovery through commercialization
Maximizing efficiency in drug research, development, and manufacturing is crucial for turning new innovations into therapeutic and financial benefits. Over the past couple of decades, pharmaceutical companies have increasingly turned to contract development and manufacturing organizations (CDMOs) for collaborations as they seek more adaptable capacity and c...
Read More
How the re-designed synthesis of a complex carbohydrate can reduce cycle time
Project challenge: Complex carbohydrate chemistry involving a linear sequence of 10 chemical transformations, unstable intermediates and column chromatographic purications. Solution design: Process research and optimization was performed to develop a robust and scalable process which was implemented on commercial scale. Telescoping of reactions reduced the number...
Read More
Alternate end-game strategies towards Nirmatrelvir synthesis: Defining a continuous flow process for the preparation of an anti-COVID drug
2023
Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...
Read More-
Discovery of MAP855, an Efficacious and Selective MEK1/2 Inhibitor with an ATP-Competitive Mode of Action.
2005
Mutations in MEK1/2 have been described as a resistance mechanism to BRAF/MEK inhibitor treatment. We report the discovery of a novel ATP-competitive MEK1/2 inhibitor with efficacy in wildtype (WT) and mutant MEK12 models. Starting from a HTS hit, we obtained selective, cellularly active ...
Read More -
Synthesis of Anti-covid Drug Nirmatrelvir Using Flow Chemistry
2005
Synthesis of the anti-covid therapeutic Nirmatrelvir by using flow chemistry to enhance efficiency of amide to nitrile conversion in a functionally and Stereochemically Embellished environment. ...
Read More -
Simple and efficient synthesis of imidazoquinoxalines and spiroquinoxalinones via pictect-spengler reaction using Wang resin, Synthetic Communications
2005
An efficient approach for the synthesis of various imidazoquinoxalines and spiroquinoxalinones has been reported from 2-(1H-imidazol-1-yl) aniline and .. ...
Read More
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.